Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.

scientific article published on August 2015

Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.BERH.2015.10.001
P698PubMed publication ID26697765

P50authorAlfons A den BroederQ45971012
P2093author name stringThasia G Woodworth
P433issue4-5
P921main subjectrheumatoid arthritisQ187255
P304page(s)543-549
P577publication date2015-08-01
P1433published inBest Practice & Research: Clinical RheumatologyQ4896784
P1476titleTreating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars
P478volume29

Reverse relations

cites work (P2860)
Q64100827In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis
Q38673326Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences
Q47104417RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus
Q41236945Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss.
Q38647660The anti-inflammatory effects of Yunnan Baiyao are involved in regulation of the phospholipase A2/arachidonic acid metabolites pathways in acute inflammation rat model

Search more.